Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior

Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of... ORIGINAL ARTICLE Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior Citalopram Ineffective in Children With Autism Bryan H. King, MD; Eric Hollander, MD; Linmarie Sikich, MD; James T. McCracken, MD; Lawrence Scahill, MSN, PhD; Joel D. Bregman, MD; Craig L. Donnelly, MD; Evdokia Anagnostou, MD; Kimberly Dukes, PhD; Lisa Sullivan, PhD; Deborah Hirtz, MD; Ann Wagner, PhD; Louise Ritz, MBA; for the STAART Psychopharmacology Network Context: Selective serotonin reuptake inhibitors are widely Main Outcome Measures: Positive response was de- prescribed for children with autism spectrum disorders. fined by a score of much improved or very much im- proved on the Clinical Global Impressions, Improve- Objectives: To determine the efficacy and safety of cital- ment subscale. An important secondary outcome was the opram hydrobromide therapy for repetitive behavior in score on the Children’s Yale-Brown Obsessive Compul- children with autism spectrum disorders. sive Scales modified for pervasive developmental disor- ders. Adverse events were systematically elicited using Design: National Institutes of Health–sponsored ran- the Safety Monitoring Uniform Report Form. domized controlled trial. Results: There was no significant difference in the rate of Setting: Six academic centers, including Mount Sinai positive response on the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior

Download PDF
8 pages
Read Article

Loading next page...
 
/lp/american-medical-association/lack-of-efficacy-of-citalopram-in-children-with-autism-spectrum-K0rjmEOC7S
Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/archgenpsychiatry.2009.30
pmid
19487623
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior Citalopram Ineffective in Children With Autism Bryan H. King, MD; Eric Hollander, MD; Linmarie Sikich, MD; James T. McCracken, MD; Lawrence Scahill, MSN, PhD; Joel D. Bregman, MD; Craig L. Donnelly, MD; Evdokia Anagnostou, MD; Kimberly Dukes, PhD; Lisa Sullivan, PhD; Deborah Hirtz, MD; Ann Wagner, PhD; Louise Ritz, MBA; for the STAART Psychopharmacology Network Context: Selective serotonin reuptake inhibitors are widely Main Outcome Measures: Positive response was de- prescribed for children with autism spectrum disorders. fined by a score of much improved or very much im- proved on the Clinical Global Impressions, Improve- Objectives: To determine the efficacy and safety of cital- ment subscale. An important secondary outcome was the opram hydrobromide therapy for repetitive behavior in score on the Children’s Yale-Brown Obsessive Compul- children with autism spectrum disorders. sive Scales modified for pervasive developmental disor- ders. Adverse events were systematically elicited using Design: National Institutes of Health–sponsored ran- the Safety Monitoring Uniform Report Form. domized controlled trial. Results: There was no significant difference in the rate of Setting: Six academic centers, including Mount Sinai positive response on the

Journal

JAMA Psychiatry – American Medical Association

Published: Jun 1, 2009

References

  • Diagnostic and Statistical Manual of Mental Disorders, Text Revision.
  • Identification and evaluation of children with autism spectrum disorders.
    Johnson, CP; Myers, SM
  • Medication use among children with autism spectrum disorders.
    Oswald, DP; Sonenklar, NA
  • An update on pharmacologic treatments for autism spectrum disorders.
    King, BH; Bostic, JQ
  • Restricted and repetitive behaviors in young children with autism spectrum disorders.
    Richler, J; Bishop, SL; Kleinke, JR; Lord, C
  • A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder.
    McDougle, CJ; Kresch, LE; Goodman, WK; Naylor, ST; Volkmar, FR; Cohen, DJ; Price, LH
  • Targeted treatments for symptom domains in child and adolescent autism.
    Hollander, E; Phillips, AT; Yeh, CC
  • A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.
    Hollander, E; Phillips, A; Chaplin, W; Zagursky, K; Novotny, S; Wasserman, S; Iyengar, R
  • Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism.
    Chandana, SR; Behen, ME; Juhász, C; Muzik, O; Rothermel, RD; Mangner, TJ; Chakraborty, PK; Chugani, HT; Chugani, DC
  • Psychotropic drug prescribing in child and adolescent learning disability psychiatry.
    Bramble, D
  • A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.
    Gordon, CT; State, RC; Nelson, JE; Hamburger, SD; Rapoport, JL
  • Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study.
    Remington, G; Sloman, L; Konstantareas, M; Parker, K; Gow, R
  • A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.
    McDougle, CJ; Naylor, ST; Cohen, DJ; Volkmar, FR; Heninger, GR; Price, LH
  • The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders.
    Posey, DJ; McDougle, CJ
  • Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders.
    Mandell, DS; Morales, KH; Marcus, SC; Stahmer, AC; Doshi, J; Polsky, DE
  • Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
    Keller, MB
  • The clinical pharmacokinetics of escitalopram.
    Rao, N
  • Use of citalopram in pervasive developmental disorders.
    Namerow, LB; Thomas, P; Bostic, JQ; Prince, J; Monuteaux, MC
  • A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders.
    Couturier, JL; Nicolson, R
  • Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders.
    Lord, C; Rutter, M; Le Couteur, A
  • Autism Diagnostic Observation Schedule: a standardized observation of communicative and social behavior.
    Lord, C; Rutter, M; Goode, S; Heemsbergen, J; Jordan, H; Mawhood, L; Schopler, E
  • The Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders.
    Scahill, L; McDougle, CJ; Williams, SK; Dimitropoulos, A; Aman, MG; McCracken, JT; Tierney, E; Arnold, LE; Cronin, P; Grados, M; Ghuman, J; Koenig, K; Lam, KS; McGough, J; Posey, DJ; Ritz, L; Swiezy, NB; Vitiello, B
  • ECDEU Assessment Manual for Psychopharmacology, Revised.
    Guy, W
  • The Repetitive Behavior Scale.
    Bodfish, JW; Symons, FW; Lewis, MH
  • The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects.
    Aman, MG; Singh, NN; Stewart, AW; Field, CJ
  • The Aberrant Behavior Checklist–Community: factor validity and effect of subject variables for adults in group homes.
    Aman, MG; Burrow, WH; Wolford, PL
  • Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
  • A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders.
    Hellings, JA; Weckbaugh, M; Nickel, EJ; Cain, SE; Zarcone, JR; Reese, RM; Hall, S; Ermer, DJ; Tsai, LY; Schroeder, SR; Cook, EH
  • Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.
    Arnold, LE; Aman, MG; Cook, AM; Witwer, AN; Hall, KL; Thompson, S; Ramadan, Y
  • Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea, S; Turgay, A; Carroll, A; Schulz, M; Orlik, H; Smith, I; Dunbar, F
  • Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology.
    Greenhill, LL; Vitiello, B; Fisher, P; Levine, J; Davies, M; Abikoff, H; Chrisman, AK; Chuang, S; Findling, RL; March, J; Scahill, L; Walkup, J; Riddle, MA
  • An open-label trial of escitalopram in pervasive developmental disorders.
    Owley, T; Walton, L; Salt, J; Guter, SJ; Winnega, M; Leventhal, BL; Cook, EH
  • Effect of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients.
    de Mendonça Lima, CA; Baumann, P; Brawand-Amey, M; Brogli, C; Jacquet, S; Cochard, N; Powell-Golay, K; Eap, CB
  • Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial [published correction appears in JAMA. 2000;283(10):1293].
    March, JS; Biederman, J; Wolkow, R; Safferman, A; Mardekian, J; Cook, EH; Cutler, NR; Dominguez, R; Ferguson, J; Muller, B; Riesenberg, R; Rosenthal, M; Sallee, FR; Wagner, KD; Steiner, H
  • Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
    Riddle, MA; Reeve, EA; Yaryura-Tobias, JA; Yang, HM; Claghorn, JL; Gaffney, G; Greist, JH; Holland, D; McConville, BJ; Pigott, T; Walkup, JT
  • Risperidone in children with autism and serious behavioral problems.
    McCracken, JT; McGough, J; Shah, B; Cronin, P; Hong, D; Aman, MG; Arnold, LE; Lindsay, R; Nash, P; Hollway, J; McDougle, CJ; Posey, D; Swiezy, N; Kohn, A; Scahill, L; Martin, A; Koenig, K; Volkmar, F; Carroll, D; Lancor, A; Tierney, E; Ghuman, J; Gonzalez, NM; Grados, M; Vitiello, B; Ritz, L; Davies, M; Robinson, J; McMahon, D
  • Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases.
    Jimmink, A; Caminada, K; Hunfeld, NG; Touw, DJ
  • Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.
    Martin, A; Koenig, K; Anderson, GM; Scahill, L
  • Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review.
    Henry, CA; Steingard, R; Venter, J; Guptill, J; Halpern, EF; Bauman, M
  • Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
    Moore, ML; Eichner, SF; Jones, JR
  • Placebo effects in developmental disabilities: implications for research and practice.
    Sandler, A
  • Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.
    King, BH; Wright, DM; Handen, BL; Sikich, L; Zimmerman, AW; McMahon, W; Cantwell, E; Davanzo, PA; Dourish, CT; Dykens, EM; Hooper, SR; Jaselskis, CA; Leventhal, BL; Levitt, J; Lord, C; Lubetsky, MJ; Myers, SM; Ozonoff, S; Shah, BG; Snape, M; Shernoff, EW; Williamson, K; Cook, EH
  • Pharmacotherapy of target symptoms in autistic spectrum disorders.
    Santosh, PJ; Baird, G

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

Sign up
for free
Start 14 day
Free Trial